Comparison of anti-endotoxin activity of apoE and apoA mimetic derivatives of a model amphipathic peptide 18A

Innate Immunity

Volumn 20, Issue 8, 2014, Pages 867-880

  Sharifov, Oleg F ^a   Nayyar, Gaurav ^a   Ternovoy, Vladimir V ^a   Palgunachari, Mayakonda N ^a   Garber, David W ^a   Anantharamaiah, G M ^a,b   Gupta, Himanshu ^a,c  

^a University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c BIRMINGHAM VA MEDICAL CENTER   (United States)

Author keywords

apolipoprotein A I mimetic peptide L 4F; Apolipoprotein E mimetic peptide Ac hE18A NH2; endotoxin; inflammation; lipopolysaccharide

Indexed keywords

APOLIPOPROTEIN A I MIMETIC PEPTIDE L 4F; APOLIPOPROTEIN E MIMETIC PEPTIDE AC HE18A NH 2; ESCHERICHIA COLI ENDOTOXIN; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; PEPTIDOMIMETIC AGENT; SUPEROXIDE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; APOLIPOPROTEIN A; APOLIPOPROTEIN E; ENDOTOXIN; PEPTIDE; PEPTIDE 18A;

ANIMAL EXPERIMENT; ANTIENDOTOXIN ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CYTOKINE PRODUCTION; DRUG ACTIVITY; DRUG EFFICACY; ENDOTOXEMIA; ESCHERICHIA COLI; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; LEUKOCYTE; MONOCYTE; MOUSE; NONHUMAN; SEROTYPE; AMINO ACID SEQUENCE; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOMIMETICS; C57BL MOUSE; CELL LINE; COMPARATIVE STUDY; DRUG EFFECTS; MOLECULAR GENETICS;

AMINO ACID SEQUENCE; ANIMALS; APOLIPOPROTEINS A; APOLIPOPROTEINS E; BIOMIMETICS; CELL LINE; ENDOTOXINS; FEMALE; HUMANS; IN VITRO TECHNIQUES; LEUKOCYTES; LIPOPOLYSACCHARIDES; MICE; MICE, INBRED C57BL; MOLECULAR SEQUENCE DATA; PEPTIDES;

EID: 84908152315     PISSN: 17534259     EISSN: 17534267     Source Type: Journal    
DOI: 10.1177/1753425913514621     Document Type: Article

References (71)

1. Cohen J. The immunopathogenesis of sepsis. Nature. 2002; 420: 885-891
2. Salvemini D, Cuzzocrea S. Oxidative stress in septic shock and disseminated intravascular coagulation. Free Radic Biol Med. 2002; 33: 1173-1185
3. Munford RS. Severe sepsis and septic shock: the role of Gram-negative bacteremia. Ann Rev Pathol. 2006; 1: 467-496
4. Nowak M, Gaines GC, Rosenberg J, et al. LPS-induced liver injury in D-galactosamine-sensitized mice requires secreted TNF-alpha and the TNF-p55 receptor. Am J Physiol Regul Integr Comp Physiol. 2000; 278: R1202 - R1209
5. Feng X, Zhang Y, Xu R, et al. Lipopolysaccharide up-regulates the expression of Fcalpha/mu receptor and promotes the binding of oxidized low-density lipoprotein and its IgM antibody complex to activated human macrophages. Atherosclerosis. 2010; 208: 396-405
6. Wiesner P, Choi SH, Almazan F, et al. Low doses of lipopolysaccharide and minimally oxidized low-density lipoprotein cooperatively activate macrophages via nuclear factor kappa B and activator protein-1: possible mechanism for acceleration of atherosclerosis by subclinical endotoxemia. Circ Res. 2010; 107: 56-65
7. Szeto CC, Kwan BC, Chow KM, et al. Endotoxemia is related to systemic inflammation and atherosclerosis in peritoneal dialysis patients. Clin J Am Soc Nephrol. 2008; 3: 431-436
8. Wiedermann CJ, Kiechl S, Dunzendorfer S, et al. Association of endotoxemia with carotid atherosclerosis and cardiovascular disease: prospective results from the Bruneck Study. J Am Coll Cardiol. 1999; 34: 1975-1981
9. Seitz CS, Kleindienst R, Xu Q, Wick G. Coexpression of heat-shock protein 60 and intercellular-adhesion molecule-1 is related to increased adhesion of monocytes and T cells to aortic endothelium of rats in response to endotoxin. Lab Invest. 1996; 74: 241-252
10. Pasterkamp G, Van Keulen JK, De Kleijn DP. Role of Toll-like receptor 4 in the initiation and progression of atherosclerotic disease. Eur J Clin Invest. 2004; 34: 328-334
11. Vikatmaa P, Lajunen T, Ikonen TS, et al. Chlamydial lipopolysaccharide (cLPS) is present in atherosclerotic and aneurysmal arterial wall - cLPS levels depend on disease manifestation. Cardiovasc Pathol. 2010; 19: 48-54
12. Lakio L, Lehto M, Tuomainen AM, et al. Pro-atherogenic properties of lipopolysaccharide from the periodontal pathogen Actinobacillus actinomycetemcomitans. J Endotox Res. 2006; 12: 57-64
13. Lalla E, Lamster IB, Hofmann MA, et al. Oral infection with a periodontal pathogen accelerates early atherosclerosis in apolipoprotein E-null mice. Arterioscler Thromb Vasc Biol. 2003; 23: 1405-1411
14. Kallio KA, Buhlin K, Jauhiainen M, et al. Lipopolysaccharide associates with pro-atherogenic lipoproteins in periodontitis patients. Innate Immun. 2008; 14: 247-253
15. Rufail ML, Schenkein HA, Koertge TE, et al. Atherogenic lipoprotein parameters in patients with aggressive periodontitis. J Periodontal Res. 2007; 42: 495-502
16. Lajunen T, Vikatmaa P, Bloigu A, et al. Chlamydial LPS and high-sensitivity CRP levels in serum are associated with an elevated body mass index in patients with cardiovascular disease. Innate Immun. 2008; 14: 375-382
17. Nakarai H, Yamashita A, Nagayasu S, et al. Adipocyte-macrophage interaction may mediate LPS-induced low-grade inflammation: potential link with metabolic complications. Innate Immun. 2012; 18: 164-170
18. Kitchens RL, Thompson PA, Munford RS, O'Keefe GE. Acute inflammation and infection maintain circulating phospholipid levels and enhance lipopolysaccharide binding to plasma lipoproteins. J Lipid Res. 2003; 44: 2339-2348
19. Kitchens RL, Wolfbauer G, Albers JJ, Munford RS. Plasma lipoproteins promote the release of bacterial lipopolysaccharide from the monocyte cell surface. J Biol Chem. 1999; 274: 34116-34122
20. Feingold KR, Funk JL, Moser AH, et al. Role for circulating lipoproteins in protection from endotoxin toxicity. Infect Immun. 1995; 63: 2041-2046
21. Levels JH, Abraham PR, van den Ende A, van Deventer SJ. Distribution and kinetics of lipoprotein-bound endotoxin. Infect Immun. 2001; 69: 2821-2828
22. Mahley RW, Rall SC Jr. Apolipoprotein E: far more than a lipid transport protein. Annu Rev Genomics Hum Genet. 2000; 1: 507-537
23. Moore RE, Navab M, Millar JS, et al. Increased atherosclerosis in mice lacking apolipoprotein A-I attributable to both impaired reverse cholesterol transport and increased inflammation. Circ Res. 2005; 97: 763-771
24. Kontush A, Chapman MJ. Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis. Pharmacol Rev. 2006; 58: 342-374
25. Navab M, Shechter I, Anantharamaiah GM, et al. Structure and function of HDL mimetics. Arterioscler Thromb Vasc Biol. 2010; 30: 164-168
26. Getz GS, Wool GD, Reardon CA. HDL apolipoprotein-related peptides in the treatment of atherosclerosis and other inflammatory disorders. Curr Pharm Design. 2010; 16: 3173-3184
27. Sharifov OF, Nayyar G, Garber DW, et al. Apolipoprotein E mimetics and cholesterol-lowering properties. Am J Cardiovasc Drugs. 2011; 11: 371-381
28. Osei-Hwedieh DO, Amar M, Sviridov D, Remaley AT. Apolipoprotein mimetic peptides: Mechanisms of action as anti-atherogenic agents. Pharmacol Ther. 2011; 130: 83-91
29. Garber DW, Datta G, Chaddha M, et al. A new synthetic class A amphipathic peptide analogue protects mice from diet-induced atherosclerosis. J Lipid Res. 2001; 42: 545-552
30. Buga GM, Navab M, Imaizumi S, et al. L-4F alters hyperlipidemic (but not healthy) mouse plasma to reduce platelet aggregation. Arterioscler Thromb Vasc Biol. 2010; 30: 283-289
31. Gupta H, White CR, Handattu S, et al. Apolipoprotein E mimetic peptide dramatically lowers plasma cholesterol and restores endothelial function in watanabe heritable hyperlipidemic rabbits. Circulation. 2005; 111: 3112-3118
32. Nayyar G, Handattu SP, Monroe CE, et al. Two adjacent domains (141-150 and 151-160) of apoE covalently linked to a class A amphipathic helical peptide exhibit opposite atherogenic effects. Atherosclerosis. 2010; 213: 449-457
33. Nayyar G, Garber DW, Palgunachari MN, et al. Apolipoprotein E mimetic is more effective than apolipoprotein A-I mimetic in reducing lesion formation in older female apo E null mice. Atherosclerosis. 2012; 224: 326-331
34. Handattu SP, Datta G, Epand RM, et al. Oral administration of L-mR18L, a single domain cationic amphipathic helical peptide, inhibits lesion formation in ApoE null mice. J Lipid Res. 2010; 51: 3491-3499
35. Anantharamaiah GM. Synthetic peptide analogs of apolipoproteins. Methods Enzymol. 1986; 128: 627-647
36. Mendez AJ, Anantharamaiah GM, Segrest JP, Oram JF. Synthetic amphipathic helical peptides that mimic apolipoprotein A-I in clearing cellular cholesterol. J Clin Invest. 1994; 94: 1698-1705
37. Anantharamaiah GM, Jones JL, Brouillette CG, et al. Studies of synthetic peptide analogs of the amphipathic helix. Structure of complexes with dimyristoyl phosphatidylcholine. J Biol Chem. 1985; 260: 10248-10255
38. Levine DM, Parker TS, Donnelly TM, et al. In vivo protection against endotoxin by plasma high density lipoprotein. Proc Natl Acad Sci U S A. 1993; 90: 12040-12044
39. Datta G, Chaddha M, Hama S, et al. Effects of increasing hydrophobicity on the physical-chemical and biological properties of a class A amphipathic helical peptide. J Lipid Res. 2001; 42: 1096-1104
40. Navab M, Anantharamaiah GM, Reddy ST, et al. Apolipoprotein A-I mimetic peptides. Arterioscler Thromb Vasc Biol. 2005; 25: 1325-1331
41. Navab M, Anantharamaiah GM, Hama S, et al. Oral administration of an Apo A-I mimetic Peptide synthesized from D-amino acids dramatically reduces atherosclerosis in mice independent of plasma cholesterol. Circulation. 2002; 105: 290-292
42. Gupta H, Dai L, Datta G, et al. Inhibition of lipopolysaccharide-induced inflammatory responses by an apolipoprotein AI mimetic peptide. Circ Res. 2005; 97: 236-243
43. Dai L, Datta G, Zhang Z, et al. The apolipoprotein A-I mimetic peptide 4F prevents defects in vascular function in endotoxemic rats. J Lipid Res. 2010; 51: 2695-2705
44. Kwon WY, Suh GJ, Kim KS, et al. 4F, apolipoprotein AI mimetic peptide, attenuates acute lung injury and improves survival in endotoxemic rats. J Trauma Acute Care Surg. 2012; 72: 1576-1583
45. Bloedon LT, Dunbar R, Duffy D, et al. Safety, pharmacokinetics, and pharmacodynamics of oral apoA-I mimetic peptide D-4F in high-risk cardiovascular patients. J Lipid Res. 2008; 49: 1344-1352
46. Watson CE, Weissbach N, Kjems L, et al. Treatment of patients with cardiovascular disease with L-4F, an apo-A1 mimetic, did not improve select biomarkers of HDL function. J Lipid Res. 2011; 52: 361-373
47. Datta G, Chaddha M, Garber DW, et al. The receptor binding domain of apolipoprotein E, linked to a model class A amphipathic helix, enhances internalization and degradation of LDL by fibroblasts. Biochemistry. 2000; 39: 213-220
48. Garber DW, Handattu S, Aslan I, et al. Effect of an arginine-rich amphipathic helical peptide on plasma cholesterol in dyslipidemic mice. Atherosclerosis. 2003; 168: 229-237
49. Datta G, White CR, Dashti N, et al. Anti-inflammatory and recycling properties of an apolipoprotein mimetic peptide, Ac-hE18A-NH(2). Atherosclerosis. 2010; 208: 134-141
50. Hasty AH, Plummer MR, Weisgraber KH, et al. The recycling of apolipoprotein E in macrophages: influence of HDL and apolipoprotein A-I. J Lipid Res. 2005; 46: 1433-1439
51. Rensen PC, Oosten M, Bilt E, et al. Human recombinant apolipoprotein E redirects lipopolysaccharide from Kupffer cells to liver parenchymal cells in rats In vivo. J Clin Invest. 1997; 99: 2438-2445
52. Van Oosten M, Rensen PC, Van Amersfoort ES, et al. Apolipoprotein E protects against bacterial lipopolysaccharide-induced lethality. A new therapeutic approach to treat Gram-negative sepsis. J Biol Chem. 2001; 276: 8820-8824
53. Ali K, Middleton M, Pure E, Rader DJ. Apolipoprotein E suppresses the type I inflammatory response in vivo. Circ Res. 2005; 97: 922-927
54. Dobson CB, Sales SD, Hoggard P, et al. The receptor-binding region of human apolipoprotein E has direct anti-infective activity. J Infect Dis. 2006; 193: 442-450
55. Sharifov OF, Xu X, Gaggar A, et al. Anti-inflammatory mechanisms of apolipoprotein a-I mimetic Peptide in acute respiratory distress syndrome secondary to sepsis. PloS One. 2013; 8: e64486 - e64486
56. Iovine NM, Elsbach P, Weiss J. An opsonic function of the neutrophil bactericidal/permeability-increasing protein depends on both its N- and C-terminal domains. Proc Natl Acad Sci U S A. 1997; 94: 10973-10978
57. Kato A, Ogasawara T, Homma T, et al. Lipopolysaccharide-binding protein critically regulates lipopolysaccharide-induced IFN-beta signaling pathway in human monocytes. J Immunol. 2004; 172: 6185-6194
58. Mueller M, Lindner B, Kusumoto S, et al. Aggregates are the biologically active units of endotoxin. J Biol Chem. 2004; 279: 26307-26313
59. Yu B, Wright SD. Catalytic properties of lipopolysaccharide (LPS) binding protein. Transfer of LPS to soluble CD14. J Biol Chem. 1996; 271: 4100-4105
60. Smythies LE, White CR, Maheshwari A, et al. Apolipoprotein A-I mimetic 4F alters the function of human monocyte-derived macrophages. Am J Physiol Cell Physiol. 2010; 298: C1538 - C1548
61. Pendyala S, Walker JM, Holt PR. A high-fat diet is associated with endotoxemia that originates from the gut. Gastroenterology. 2012; 142: 1100-1101,e2
62. Cani PD, Amar J, Iglesias MA, et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes. 2007; 56: 1761-1772
63. de Bont N, Netea MG, Demacker PN, et al. Apolipoprotein E knock-out mice are highly susceptible to endotoxemia and Klebsiella pneumoniae infection. J Lipid Res. 1999; 40: 680-685
64. Andra J, Koch MH, Bartels R, Brandenburg K. Biophysical characterization of endotoxin inactivation by NK-2, an antimicrobial peptide derived from mammalian NK-lysin. Antimicrob Agents Chemother. 2004; 48: 1593-1599
65. White CR, Smythies LE, Crossman DK, et al. Regulation of pattern recognition receptors by the apolipoprotein A-I mimetic peptide 4F. Arterioscler Thromb Vasc Biol. 2012; 32: 2631-2639
66. Jackson DG. Human leucocyte heparan sulphate proteoglycans and their roles in inflammation. Biochem Soc Trans. 1997; 25: 220-224
67. Parish CR. The role of heparan sulphate in inflammation. Nat Rev Immunol. 2006; 6: 633-643
68. Piccinini AM, Midwood KS. DAMPening inflammation by modulating TLR signalling. Mediators Inflamm. 2010; 2010:
69. Handattu SP, Garber DW, Horn DC, et al. ApoA-I mimetic peptides with differing ability to inhibit atherosclerosis also exhibit differences in their interactions with membrane bilayers. J Biol Chem. 2007; 282: 1980-1988
70. Zughaier SM, Zimmer SM, Datta A, et al. Differential induction of the toll-like receptor 4-MyD88-dependent and -independent signaling pathways by endotoxins. Infect Immun. 2005; 73: 2940-2950
71. Lorenz E, Patel DD, Hartung T, Schwartz DA. Toll-like receptor 4 (TLR4)-deficient murine macrophage cell line as an in vitro assay system to show TLR4-independent signaling of Bacteroides fragilis lipopolysaccharide. Infect Immun. 2002; 70: 4892-4896